This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SBOT vs. IRWD, ENTA, NLTX, PROC, RAPT, TNXP, ZNTL, SLN, COYA, and BHSTShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Ironwood Pharmaceuticals (IRWD), Enanta Pharmaceuticals (ENTA), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), RAPT Therapeutics (RAPT), Tonix Pharmaceuticals (TNXP), Zentalis Pharmaceuticals (ZNTL), Silence Therapeutics (SLN), Coya Therapeutics (COYA), and BioHarvest Sciences (BHST). These companies are all part of the "medical" sector. Stellar Biotechnologies vs. Ironwood Pharmaceuticals Enanta Pharmaceuticals Neoleukin Therapeutics Procaps Group RAPT Therapeutics Tonix Pharmaceuticals Zentalis Pharmaceuticals Silence Therapeutics Coya Therapeutics BioHarvest Sciences Stellar Biotechnologies (NASDAQ:SBOT) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership. Is SBOT or IRWD more profitable? Ironwood Pharmaceuticals has a net margin of -0.65% compared to Stellar Biotechnologies' net margin of -1,782.64%. Ironwood Pharmaceuticals' return on equity of -0.96% beat Stellar Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Stellar Biotechnologies-1,782.64% -51.12% -48.37% Ironwood Pharmaceuticals -0.65%-0.96%0.74% Do insiders and institutionals hold more shares of SBOT or IRWD? 1.7% of Stellar Biotechnologies shares are held by institutional investors. 7.8% of Stellar Biotechnologies shares are held by company insiders. Comparatively, 12.9% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, SBOT or IRWD? Stellar Biotechnologies has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Stellar Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStellar Biotechnologies$210K164.98-$5.03M-$1.76-3.69Ironwood Pharmaceuticals$351.41M0.41-$1.00B-$0.03-29.62 Do analysts rate SBOT or IRWD? Ironwood Pharmaceuticals has a consensus target price of $4.78, suggesting a potential upside of 438.36%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Stellar Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stellar Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ironwood Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Does the MarketBeat Community believe in SBOT or IRWD? Ironwood Pharmaceuticals received 280 more outperform votes than Stellar Biotechnologies when rated by MarketBeat users. However, 66.48% of users gave Stellar Biotechnologies an outperform vote while only 60.68% of users gave Ironwood Pharmaceuticals an outperform vote. CompanyUnderperformOutperformStellar BiotechnologiesOutperform Votes23466.48% Underperform Votes11833.52% Ironwood PharmaceuticalsOutperform Votes51460.68% Underperform Votes33339.32% Does the media favor SBOT or IRWD? In the previous week, Ironwood Pharmaceuticals had 8 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 0 mentions for Stellar Biotechnologies. Ironwood Pharmaceuticals' average media sentiment score of 0.82 beat Stellar Biotechnologies' score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Stellar Biotechnologies Neutral Ironwood Pharmaceuticals Positive SummaryIronwood Pharmaceuticals beats Stellar Biotechnologies on 12 of the 17 factors compared between the two stocks. Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.65M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-3.697.1422.1418.40Price / Sales164.98238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book3.076.266.664.18Net Income-$5.03M$142.48M$3.21B$247.71M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$6.50-2.4%N/A+119.1%$34.65M$210,000.00-3.6925IRWDIronwood Pharmaceuticals4.5713 of 5 stars$0.70-3.0%$4.78+578.6%-89.0%$114.06M$351.41M-23.50220Gap UpENTAEnanta Pharmaceuticals3.9988 of 5 stars$5.23+2.5%$17.25+229.8%-55.3%$111.57M$66.59M-1.06160News CoveragePositive NewsNLTXNeoleukin TherapeuticsN/A$11.49+6.7%N/A-48.5%$107.98MN/A-3.6990News CoverageHigh Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-65.2%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeRAPTRAPT Therapeutics3.7165 of 5 stars$0.78-1.1%$4.00+411.5%-88.7%$103.23M$1.53M-0.2880Positive NewsGap DownTNXPTonix Pharmaceuticals2.3802 of 5 stars$14.96-4.8%$585.00+3,810.4%-96.5%$101.09M$10.09M0.0050ZNTLZentalis Pharmaceuticals2.8339 of 5 stars$1.36+5.4%$8.24+506.2%-87.0%$97.66M$67.43M-0.55160News CoveragePositive NewsSLNSilence Therapeutics2.4475 of 5 stars$3.20+1.9%$40.67+1,170.8%-84.5%$95.78M$43.26M-2.04100News CoverageCOYACoya Therapeutics2.4945 of 5 stars$5.71+8.6%$17.00+197.7%-26.7%$95.50M$3.55M-8.786Analyst ForecastNews CoveragePositive NewsHigh Trading VolumeBHSTBioHarvest SciencesN/A$5.81+2.8%$13.00+123.8%N/A$95.43M$25.19M-4.65N/AUpcoming EarningsNews Coverage Related Companies and Tools Related Companies IRWD Competitors ENTA Competitors NLTX Competitors PROC Competitors RAPT Competitors TNXP Competitors ZNTL Competitors SLN Competitors COYA Competitors BHST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBOT) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
